ReGen Declines "Futile" 510(k) Rescission Hearing But Plans Legal Challenge
This article was originally published in The Gray Sheet
Executive Summary
ReGen Biologics says it is considering several last-ditch options to keep its collagen meniscus scaffold device on the U.S. market, but they do not include another hearing with FDA.